Kiora Pharmaceuticals (KPRX) investor relations material

Executive summary

• Focus on developing innovative therapies for retinal diseases, with KIO-301 and KIO-104 as lead candidates addressing significant unmet needs in the US market.

• KIO-301 targets over 100,000 US patients with retinitis pigmentosa and is in Phase 2 ABACUS-2 trial, with topline data expected in Q3 2027; KIO-104 targets 1.2 million US patients with retinal inflammatory diseases and is advancing through Phase 2 KLARITY trial.

• Strategic partnerships with Théa (global rights outside Asia) and Senju (option for Asia) provide milestone and royalty opportunities, including $16M upfront and up to $285M in milestones from Théa, and $1.25M upfront and up to $110M in milestones from Senju.

• Cash and short-term investments totaled $16.8M at June 30, 2026, supporting operations into late 2028, with additional financial flexibility from a $24M private placement.

• Exploring strategic transactions to diversify and expand the development pipeline, potentially accelerating warrant exercises.

Financial highlights

• Cash and short-term investments increased to $16.8M at June 30, 2026, mainly due to equity financing and private placements.

• Net loss for Q2 2026 was $2.08M–$2.1M, improved from $2.15M–$2.2M in Q2 2025.

• Over $7M reimbursed for R&D through partnerships to date, with all KIO-301 R&D expenses reimbursed by partners.

• Private placement in April 2026 raised $4.9M net proceeds; up to $24M secured in a subsequent private placement, with $5M received upfront.

• Net loss per share for Q2 2026 was $0.34, improved from $0.54 in Q2 2025.

Outlook and guidance

• Current resources, expected collaboration reimbursements, and capital are projected to fund operations into late 2028.

• Last patient, first visit for ABACUS-2 expected in Q1 2027, with topline data in Q3 2027; initial clinical data from KLARITY trial anticipated in late 2026.

• Additional financing will be needed for future commercialization and development beyond current plans.